Loading patent…
AssigneeYale University
InventorsAnthony N. Van Den Pol, Guido Wollmann
Estimating the term…
Methods of treating cancer including administering to a subject with cancer a pharmaceutical composition including an effective amount of a chimeric VSV virus are disclosed. The chimeric viruses are based on a VSV background where the VSV G protein is replaced with one or more heterologous viral glycoproteins. In the most preferred embodiment, the VSV G protein is replaced with the glycoprotein from Lassa virus or a functional fragment thereof. The resulting chimeric virus is an oncolytic virus that is attenuated and safe in the brain, yet still retains sufficient oncolytic activity to infect and destroy cancer cells such glioblastoma, and to generate an immune response against infected cancer cells. Methods of using chimeric viruses as a platform for immunization against other pathogenic microbes are also provided.
A method of treating cancer comprising administering to a subject with cancer a pharmaceutical composition comprising an effective amount of a chimeric Vesicular stomatitis Indiana virus (VSV) virus to treat the cancer,
A method of reducing one or more symptoms of cancer in a subject comprising administering to a subject with cancer a pharmaceutical composition comprising an effective amount of a chimeric VSV virus to reduce one or more symptoms of the cancer in the subject,
A method of treating a subject for cancer comprising
A method of preparing cells for adaptive T cell therapy comprising administering to a subject with cancer a pharmaceutical composition comprising an effective amount of a chimeric VSV virus to increase the number of cytotoxic T cells (CTL) which can directly kill the cancer,
A method of preparing cells for adaptive T cell therapy comprising administering to a subject with cancer a pharmaceutical composition comprising an effective amount of a chimeric VSV virus to increase the number of CD4+ T cells which can direct an immune response against the cancer,
A pharmaceutical dosage unit comprising an effective amount of a chimeric VSV virus to treat cancer in subject in need thereof, wherein the chimeric VSV virus comprises a VSV background with one or more heterologous viral glycoproteins in place of the VSV G-protein,
A method of vaccinating a subject against an antigen comprising administering the subject an effective amount of a chimeric VSV virus comprising a VSV background with one or more heterologous viral glycoproteins in place of the VSV G-protein and an antigen, in an effective amount to enhance an immune response against the antigen,
Dependencies are inferred from the claim text.